|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500098012 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-28 11:23:59 |
|
注册时间: Date of Registration: |
2025-02-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
胸膜感染的病原学及临床分析 |
|
Public title: |
Etiological and clinical analysis of pleural infection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
胸膜感染的病原学及临床分析 |
|
Scientific title: |
Etiological and clinical analysis of pleural infection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周靓 |
研究负责人: |
王凯歌 |
|
Applicant: |
Liang Zhou |
Study leader: |
Kaige Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 159 2861 1364 |
研究负责人电话: Study leader's telephone: |
+86 28 8542 3331 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2022324020160@stu.scu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
532951643@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Provinc |
Study leader's address: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Provinc |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025年审(151)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Committee of West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-24 00:00:00 |
||
|
伦理委员会联系人: |
邓绍林 |
||
|
Contact Name of the ethic committee: |
Deng Shaolin |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Provinc |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 85423637 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
其他 |
||||||||||||||||||||||
|
Source(s) of funding: |
Other |
||||||||||||||||||||||
|
Target disease: |
pleural infection |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
1. 明确胸膜感染患者的临床特征 2. 明确胸膜感染患者的病原学特征 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Clarify the clinical characteristics of patients with pleural infection 2. Clarify the etiological characteristics of patients with pleural infection |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 临床诊断标准(符合以下任一项): ① 发热 ② 外周血白细胞计数升高 ③ 血清C反应蛋白升高 2. 实验室或影像学证据(符合以下任一项): ① 胸腔积液肉眼可见脓性 ② 胸腔积液细菌培养阳性 ③ 胸腔积液革兰氏染色见细菌 ④ 胸腔积液生化检查: pH≤7.2;若无法获取pH值,则需满足:LDH>1000 U/L且葡萄糖≤2.2 mmol/L ⑤ 增强CT显示:胸膜感染(表现为伴有肺实变且强化的胸腔积液)且已排除其他感染源 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Clinical diagnostic criteria (meeting any one of the following): (1) Fever (2) Elevated peripheral blood white blood cell count (3) Elevated serum C-reactive protein 2. Laboratory or imaging evidence (meeting any one of the following): (1) Visible purulent pleural effusion to the naked eye (2) Positive bacterial culture of pleural effusion (3) Bacteria seen on Gram staining of pleural effusion (4) Biochemical examination of pleural effusion: pH <= 7.2; if pH value cannot be obtained, then it must meet: LDH > 1000 U/L and glucose <= 2.2 mmol/L (5) Enhanced CT shows: pleural infection (manifested as pleural effusion with lung consolidation and enhancement) and other infection sources have been excluded |
||||||||||||||||||||||
|
排除标准: |
① 年龄<18岁 ② 感染侧曾行肺切除术 ③ 无法获取同时获取:胸腔积液常规检查、生化检查及病原学检测结果 ④ 缺少胸腔引流前的胸腔超声数据 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) <18 years old (2) Pulmonary resection was performed on the infected side (3) Can not obtain at the same time: pleural effusion routine examination, biochemical examination and etiological detection results (4) Lack of thoracic ultrasound data before thoracic drainage |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-03-12 00:00:00至 To 2026-01-24 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-03-12 00:00:00 至 To 2025-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过邮箱532951643@qq.com 联系研究负责人,且采用临床试验公共管理平台ResMan向公众开放查询, http://www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact by E-mail of study leader (532951643@qq.com),and the data will be published in the public management platform of clinical trials ResMan, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |